Home » Roche’s Tecentriq Gains NICE Recommendation After Prior Rejection
Roche’s Tecentriq Gains NICE Recommendation After Prior Rejection
Drugs Submissions and Approvals
The U.K.’s National Institute for Health and Care Excellence (NICE), which previously shot down Roche’s immunotherapy Tecentriq (atezolizumab) for use in treating non-small cell lung cancer (NSCLC), reversed its decision, offering its recommendation for patients whose disease progressed following standard chemotherapy.
NICE’s reversal was based on Roche’s data from a Phase 3 study showing that patients with advanced NSCLC lived 4.2 months longer than those who received standard chemotherapy and experienced fewer side effects.
Tecentriq is a monoclonal antibody that binds with a protein, PD-L1, and stops it from camouflaging cancer cells to avoid detection and removal by the immune system.